Key Takeaways
- Sequential rebound, YoY still soft: Revenue rose 13% QoQ to ₹891 crores, but declined 2% YoY, with H1 broadly flat and in line with guidance.
- Discovery Services showing early recovery: Pilot-project collaborations with biopharma clients seeking China alternatives drove the first positive signs, though the recovery is nascent.
- Margins recovered sharply from Q1 trough: Operating EBITDA margin rebounded to 27% from 22% in Q1, back within range YoY, as revenue scaled sequentially.
- CFO transition underway: Sibaji Biswas resigned; Deepak Jain, with experience at Ather, Apple and P&G, takes over as CFO from December 1, 2024.
- What to watch next quarter: Whether the promised positive revenue trajectory in Q3 materializes, the pace of Discovery Services recovery, and the Unit III biologics facility going live in H2.
Sequential Recovery After a Weak Q1
- Q2 pulled out of the Q1 trough: Revenue of ₹891 crores improved from Q1's ₹790 crores, EBITDA margin recovered to 27.5% from 21.5%, and EBIT margin to 15.0% from 8.0%, though all metrics remained below the prior-year quarter.
- H1 held flat, not down: H1 FY25 revenue of ₹1,681 crores was broadly flat YoY, consistent with the company's full-year guidance framework.
- Q4 FY24 one-offs distort the view: The prior-year Q4 included a ₹20.3 crore inventory provision reversal and a ₹23.2 crore tax provision reversal, while Q1 FY25 benefited from a ₹5.1 crore depreciation reduction from an asset-life change, making sequential comparisons cleaner than YoY ones.
- FX swung to a tailwind: Foreign exchange moved from a ₹17.9 crore loss in Q2 FY24 to a ₹4.3 crore gain in Q2 FY25, and from a ₹33.4 crore loss in H1 FY24 to a ₹1.0 crore gain in H1 FY25.
- Exceptional items absent in Q2: Q2 FY25 had no exceptional items, versus ₹5.5 crore in transaction costs for the Stelis Biopharma acquisition in Q2 FY24; H1 FY25 included a ₹21.2 crore exceptional gain from an insurance claim on a 2016 fire incident.
Biswas: "With improving sequential revenues, our operating EBITDA margin came in at 27% for the quarter compared to 22% in the first quarter and broadly within range year-on-year."
Discovery Services: Early Recovery, China-Plus-One Driver
- Pilot projects signal the turn: Early positive signs in Discovery Services are driven by collaborations on pilot projects with large and mid-sized biopharma clients, who are actively looking for alternatives to China to rebalance their supply chains.
- Client engagement metrics rising: The company saw increased RFPs, on-site visits and more than 60 audits in the first six months, a 36% increase compared to the same period last year, suggesting a broadening pipeline.
- Capacity being added ahead of demand: The company continues to add capacity and capabilities in Discovery Services at Bangalore and Hyderabad campuses in areas such as antibody-drug conjugates, peptides and oligonucleotides, positioning for the expected supply-chain shift.
Hunt: "I am pleased with the early positive signs of recovery in Discovery Services, largely driven by collaborations on pilot projects with large and mid-sized biopharma clients looking for alternatives to China to rebalance their supply chains."
Development & Manufacturing: Biologics Build-Out
- Biologics manufacturing sustained delivery: The Development and Manufacturing Services segment saw sustained delivery in biologics manufacturing and a higher number of process development projects compared to last year in small molecules.
- Unit III on track for H2 FY25: The repurposed biologics manufacturing facility acquired from Stelis in December 2023 remains on track to commence operations in H2 FY25, with single-use bioreactors, a development suite for clinical supply of drug substances, and two high-speed vial filling lines offering plug-and-play manufacturing platforms.
- Healthy client interest in biologics: Management cited healthy interest from clients in biologics, with proven capabilities and the additional manufacturing capacity coming online in H2 FY25 as a demand catalyst.
Cost Structure: Staff Costs the Pressure Point
- Staff costs rose faster than revenue: Staff costs increased 12.5% YoY in Q2 and 11.4% in H1, with the cost-to-revenue ratio deteriorating 395 bps to 30.4% in Q2 and 380 bps to 31.2% in H1, the single largest margin drag.
- Material costs provided a partial offset: Material costs declined 11.4% YoY in Q2 and 4.1% in H1, with the cost-to-revenue ratio improving 280 bps to 26.6% in Q2, cushioning the staff-cost impact.
- Other expenses also rose: Other expenses increased 16.0% YoY in Q2 and 9.8% in H1, with the cost-to-revenue ratio deteriorating 207 bps to 13.3% in Q2, reflecting investments in digitization, commercial capabilities and new technology.
- Depreciation ticking up: Depreciation and amortisation rose 6.0% YoY in Q2 and 5.4% in H1, consistent with ongoing capacity expansion; capital work-in-progress increased from ₹837 crores in March 2024 to ₹904 crores in September 2024.
Balance Sheet & Capital Position
- Net cash position strengthened: Cash and cash equivalents rose from ₹85.7 crores in March 2024 to ₹220.6 crores in September 2024, while inventories decreased from ₹238.5 crores to ₹170.5 crores, releasing working capital.
- Receivables ticked up: Trade receivables increased from ₹441.6 crores to ₹483.9 crores over the same period, a manageable rise alongside the sequential revenue recovery.
- Investment capacity intact: Management highlighted a robust balance sheet with a strong net cash position, enabling continued investment in strategic areas including digitization, commercial capabilities and new technology to support growth.
Leadership Changes
- CFO transition: Sibaji Biswas, Executive Director and CFO, resigned to pursue other opportunities and will step down from the Board on November 30, 2024. Deepak Jain, who joined Syngene in September 2024 from Ather Energy and previously served as India CFO for First Advantage and Apple, takes over as CFO from December 1, 2024.
- New Chief Scientific Officer: Jayashree Aiyar was appointed CSO and joins the Executive Committee with immediate effect. She joined Syngene in 2016 as VP and Head of Discovery Biology, holds a PhD in Immunology from AIIMS, New Delhi, and brings over 25 years of experience.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year revenue guidance | Remain on track to deliver within guidance range | FY25 |
| Positive revenue trajectory | Expect a positive change in revenue trajectory | Q3 FY25 |
| Unit III biologics facility | Commence operations with single-use bioreactors, development suite and two vial filling lines | H2 FY25 |
| Medium-to-long-term growth | Leverage recent investments in research and CDMO businesses | Medium to long term (undated) |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue from operations | ₹891 cr, down 2% YoY, up 13% QoQ |
| Revenue from operations (constant currency) | down 3% YoY |
| Reported EBITDA | ₹261 cr, down 5% YoY |
| Reported EBITDA margin | 28.8%, vs 29.6% in Q2 FY24 |
| Operating EBITDA margin | 27%, vs 22% in Q1 FY25 |
| PAT before exceptional item | ₹106 cr, down 13% YoY |
| PAT margin (before exceptional items) | 11.7%, vs 13.1% in Q2 FY24 |
| PAT after exceptional item | ₹106 cr, down 9% YoY |
| H1 FY25 revenue from operations | ₹1,681 cr, down 2% YoY, broadly flat in line with guidance |
| H1 FY25 PAT after exceptional item | ₹182 cr, down 13% YoY |
| Staff costs | ₹271 cr, 30.4% of revenue, up 12.5% YoY |
| Foreign exchange gain/(loss), net | gain of ₹4.3 cr, vs loss of ₹17.9 cr in Q2 FY24 |
| Audits in first 6 months | more than 60, a 36% increase YoY |
| Cash and cash equivalents | ₹220.6 cr as at 30 Sep 2024, vs ₹85.7 cr as at 31 Mar 2024 |